Novartis Price Prediction and Hype Density Breakdown

NVS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

We analyze noise-free headlines and recent hype associated with Novartis AG which may create opportunities for some arbitrage if properly timed. With Novartis hype-based prediction module you can estimate the value of Novartis AG from the prospective of Novartis response to recently generated media hype and the effects of current headlines on its competitors. The module also provides analysis of price elasticity to changes in media outlook on Novartis over a specific investment horizon. Please see also Novartis Basic Forecasting Models to cross-verify your projections.
Horizon     30 Days    Login   to change

Novartis After-Hype Price Density Analysis

 Next price density 
      Expected price to next headline 

Novartis Estimiated After-Hype Price Volatility

Current Value
December 9, 2019
After-hype Price
Novartis is very steady asset. Analysis and calculation of next after-hype price of Novartis AG is based on 3 months time horizon.

Novartis Next Price Analysis

Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
 0.07  0.80  0.01   0.01  7 Events / Month6 Events / MonthIn about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility

Novartis Hype Timeline

On the 9th of December Novartis AG is traded for 92.53. The entity has historical hype elasticity of 0.01 and average elasticity to hype of competition of 0.01. Novartis AG is estimated to increase in value after the next headline with price going to jump to 92.54. The average volatility of media hype impact on the company stock price is about 421.05%. The price escalation on the next news is projected to be 0.01% where as daily expected return is now at 0.07%. The volatility of related hype on Novartis is about 423.28% with expected price after next announcement by competition of 92.54. The company reported last year revenue of 54.93 B. Total Income to common stockholders was 7.05 B with profit before taxes, overhead, and interest of 36.08 B. Considering 30-days investment horizon, the next estimated press release will be in about 7 days.
Please see also Novartis Basic Forecasting Models to cross-verify your projections.

Novartis Related Hype Analysis

At Risk
Johnson Johnson(0.11) 9 per month 1.18  0.07  1.88 (1.63)  8.27 
Allergan Plc(0.06) 9 per month 0.00  0.25  1.10 (0.59)  2.21 
Astrazeneca PLC 0.20 11 per month 1.05  0.0337  1.75 (1.89)  7.62 
Pfizer 0.23 10 per month 0.81  0.0153  1.86 (1.45)  4.36 
GlaxoSmithKline PLC(0.10) 10 per month 0.96  0.07  1.52 (1.57)  4.17 
Merck Company 0.25 11 per month 1.31 (0.0144)  1.91 (2.13)  6.54 
Bristol Myers Squibb Company 0.14 7 per month 0.60  0.30  1.99 (1.15)  4.45 
Novartis AG 0.19 7 per month 0.91 (0.0167)  1.00 (1.18)  3.53 
Eli Lilly And Company 0.87 9 per month 1.19  0.0199  1.79 (1.70)  5.15 
Gilead Sciences 0.28 6 per month 1.45 (0.0046)  2.07 (2.53)  6.39 
Please see also Novartis Basic Forecasting Models to cross-verify your projections. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.